E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure
Elias Jabbour,Jorge E. Cortes,Hagop M. Kantarjian,Sergio Giralt,Dan Jones,Roy B. Jones,Francis J. Giles,Borje S. Andersson,Richard E. Champlin,Marcos de Lima +9 more
TL;DR: Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations, and seven patients are alive (6 in CMR) for a median of 19 months.
Journal ArticleDOI
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
Elias Jabbour,Hagop M. Kantarjian,Susan O'Brien,Jenny Shan,Guillermo Garcia-Manero,William G. Wierda,Farhad Ravandi,Gautam Borthakur,Mary Beth Rios,Jorge E. Cortes +9 more
TL;DR: Patients with poor performance status and no previous cytogenetic response to imatinib therapy have a low likelihood of responding to second-generation TKI with poor event-free survival and therefore should be offered additional treatment options.
Journal ArticleDOI
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
TL;DR: Clinical trial data from an evaluation of the response of specific mutant BCR‐ABL clones to TKIs is needed to establish the role of mutation testing in the management of CML, and comorbidities and drug safety profiles should be the basis for choosing a second‐line agent.
Journal ArticleDOI
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Koichi Takahashi,Keyur P. Patel,Carlos E. Bueso-Ramos,Jianhua Zhang,Curtis Gumbs,Elias Jabbour,Tapan M. Kadia,Michael Andreff,Marina Konopleva,Courtney D. DiNardo,Naval Daver,Jorge E. Cortes,Zeev Estrov,Andrew Futreal,Hagop M. Kantarjian,Guillermo Garcia-Manero +15 more
TL;DR: Evidence is provided that TP53 mutations are independently prognostic in MDS patients treated with HMA and while TP53-mutated M DS patients initially respond well to HMA, their duration of response is significantly shorter than WT patients.
Journal ArticleDOI
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
TL;DR: A comprehensive review will focus on the recent advances and future directions in novel therapeutic strategies in adult ALL, allowing for novel approaches that reduce reliance on intensive cytotoxic chemotherapy and hematopoietic stem cell transplantation in first remission.